GAITHERSBURG, Md., May 29 /PRNewswire/ -- MaxCyte, Inc., a clinical stage therapeutics company and pioneer in cell loading systems, announces two presentations at the ASGT 10th Annual Meeting. The meeting is being held May 30 - June 3, 2007 in Seattle, Washington.
Dr. James Brady will speak on “Large Scale Production of Lentiviral Vectors Using Adherent and Suspension-Adapted Cells” at 2:15 p.m. Friday, June 1, 2007 during the Cell Processing and Vector Production Oral Abstract Session. Dr. Linhong Li will give a presentation on the “Development of Immunotherapeutics for Mantle Cell Lymphoma” at 5:00 p.m. Thursday, May 31, 2007 during the Cancer Immunotherapy Poster Session.
About MaxCyte
MaxCyte is a clinical-stage cell therapeutics company with a rapidly growing pipeline of product development partnerships in cell-based therapies. The Company’s proprietary ex vivo cell loading technology overcomes critical obstacles such as safety, scalability and reproducibility which are fundamental to successful cell-based therapies. MaxCyte has demonstrated the value of its versatile technology in partnered therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers. Current clinical programs with MaxCyte-engineered cells include: a Phase I/II clinical study for treatment of chronic lymphocytic leukemia (CLL) and a Phase IIa study using engineered stem cells for the treatment of primary Pulmonary Arterial Hypertension (PAH). In addition there are advanced preclinical programs in oncology and regenerative medicine. More than 16 commercial and academic partners are currently using the MaxCyte technology. The MaxCyte system has an FDA Master File in place at CBER.
For more information, visit http://www.maxcyte.com.
This press release may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management’s current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties.
MaxCyte, Inc.
CONTACT: Anthony Recupero, Ph.D., Vice President Business Development ofMaxCyte, Inc., +1-301-944-1700
Web site: http://www.maxcyte.com/
